Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Larotrectinib

EU orphan designation number: EU/3/18/2098   
Active ingredient: Larotrectinib
Indication: Treatment of papillary thyroid cancer
Sponsor: Bayer AG
D-51368 Leverkusen, Deutschland

  

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/11/2018 Orphan designation EMA/OD/117/18 (2018)7808 of 19/11/2018